Chemodex

Bupivacaine hydrochloride monohydrate

CHF 61.00
In stock
CDX-B0326-G0011 gCHF 61.00
CDX-B0326-G0055 gCHF 95.00
More Information
Product Details
Synonyms 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; 1-Butyl-2',6'-pipecoloxylidide
Product Type Chemical
Properties
Formula C18H28N2O . HCl . H2O
MW 288.4. 36.5 . 18.0
CAS 73360-54-0
RTECS TK6125000
Source/Host Chemicals Synthetic
Purity Chemicals ≥98% (T)
Appearance White to off-white powder.
Solubility Soluble in water (10mg/ml), DMSO (20mg/ml) or ethanol (20mg/ml). Slightly soluble in chloroform or acetone.
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key HUCIWBPMHXGLFM-UHFFFAOYSA-N
Smiles CCCCN1CCCCC1C(NC2=C(C)C=CC=C2C)=O.Cl.O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at RT.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Bupivacaine is an amino amide local anesthetic that decreases current amplitude and inhibits whole cell K+ currents in Ca2+-activated K+ channels and N-type voltage-gated (KCNA and KCNC) K+ channels. Bupivacaine also inhibits voltage-gated Na+ channels and tandem pore domain (TASK-2/KCNK-5) K+ channels. The compound is cytotoxic at high concentrations inducing apoptosis and/or necrosis by interference with the mitochondrial energy transduction. Shown to inhibit aerobic ATP synthesis by (i) uncoupling of the oxidative phosphorylation (OXPHOS) and (ii) inhibition of the respiratory complex. Other mechanisms include inhibition of the carnitine-acylcarnitine translocase or activation of the mitochondrial permeability transition pore (MPTP). The analgesic effects of bupivicaine are thought to potentially be due to its binding to the prostaglandin E2 receptors, subtype EP1 (PGE2EP1), which inhibits the production of prostaglandins, thereby reducing fever, inflammation, and hyperalgesia. It is employed as cAMP production inhibitor, it acts as a surfactant molecule possessing both hydrophilic and lipophilic properties, adrenergic antagonist and cholinesterase inhibitor.

Product References

(1) F. Sztark, et al.; Anesthesiology 88, 1340 (1998) | (2) G.L. Weinberg, et al.; Anesthesiology 92, 523 (2000) | (3) C.W. Hoenemann, et al.; Anesth. Analg. 93, 628 (2001) | (4) W. Irwin, et al.; J. Biol. Chem. 277, 12221 (2002) | (5) W.H. Kluge, et al.; Scand. J. Clin. Lab Invest. 62, 495 (2002) | (6) A. Unami, et al.; J. Toxicol. Sci. 28, 77 (2003) | (7) C.H. Kindler, et al.; J. Pharmacol. Exp. Ther. 306, 84 (2003) | (8) J. Nilsson, et al.; Biophys. J. 95, 5138 (2008) | (9) O. Cela, et al. ; Mitochondrion 10, 487 (2010) | (10) J. Lu, et al.; Eur. J. Pharmacol. 657, 51 (2011) | (11) M. Harato, et al.; BMC Neurosci. 13, 149 (2012) | (12) P. Martin, et al.; Channels 6, 174 (2012) | (13) M.A. Paganelli & G.K. Popescu; J. Neurosci. 35, 831 (2015)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.